FDA Cites Pfizer Over Contaminated Vials at Hospira Facility in Kansas

Pfizer’s Hospira is drawing scrutiny from the FDA in a warning letter for failing to fully investigate quality defects, such as the presence of cardboard, in batches of injections and neglecting to take corrective measures.
Source: Drug Industry Daily